Pharma Capital
Market: LSE
52-week High/Low: 16.30p / 11.00p
Sector: Health Care, Equipment & Services
Market Cap: 8.40M
Phone: +351 919 033 171
Address: Core Technology Facility, 46 Grafton Street, Manchester M13 9NT.

WideCells Group PLC is a worldwide healthcare services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment.


** Click here to read a full statement from the Group CEO Joao Andrade on the momentous news that WideCells Group has been included in the DISRUPT 100 index as the 21st most disruptive firm in the world **

WideCells Group

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in WideCells Group

WideCells Group Snapshot

Dr Graham Hine
Non-Executive Director and Chairman

Graham is a technology entrepreneur with a background in successfully leading, growing and exiting technology companies. His career began with Philips, where he moved through semi-conductor development into international sales and marketing of the resultant products. Subsequently, Graham has had over 20 years' experience as CEO to companies including Capteur Sensors and Analysers Ltd which manufactured chemical measuring equipment including gas sensors, P2i Ltd, which is involved in liquid repellent nanotechnology, Hardide Plc, an AIM listed, advanced surface coating technology company and SGX Sensortech Limited, which sells gas and x-ray sensor technologies.

João Andrade
Chief Executive Officer

João, one of the co-founders of the WideCells business, has a strong background in marketing and international business development, and brings his considerable experience business experience, strategic thinking and industry specific knowledge. João has over eight years senior experience in the stem cell market, and, prior to founding WideCells, served in key roles at two European cord blood banks and service providers, with operations in several countries.

Lopes Gil
Chief Operating Officer

Lopes Gil is a co-founder of WideCells, and has over 25 years' experience working as an area manager in Merck KGaA and Mylan N.V. in Portugal, creating and establishing complex business operations. In addition, he has extensive business experience in international marketing, strategic planning and studies in the pharmaceutical industry. Lopes was previously Chief Finance Strategist at an European cord blood bank, where he was focused on developing its international cell banking services. He holds a degree in management from Instituto Superior Miguel Torga, and an MBA from Universidad San Pablo-CEU.

Dr Peter Hollands
Chief Scientific Officer

Peter trained at Cambridge University under the supervision of Professor Sir Robert Edwards FRS, the inventor of IVF and Nobel Laureate, gaining a PhD from Cambridge University in stem cell technology. Peter held a post-doctorate position as a Senior Embryologist at the first IVF clinic in the world, Bourn Hall Clinic, and has carried out research in stem cell technology, has written numerous papers and book chapters on stem cell technology, and has been invited to lecture on stem cell technology in the Vatican, House of Lords and the Canadian Parliament. He has also been involved in clinical transplantation as Quality Manager in the Bone Marrow Transplantation Unit at Great Ormond Street Hospital for Children. Most recently, Peter was Chief Scientific Officer of Smart Cells Information Ltd., a UK cord blood bank, and Cells for Life Ltd. in Canada.

David Bridgland
Chief Financial Officer

David studied engineering at Cambridge University and is a Chartered Accountant. He has over 20 years of business experience in a range of companies, from privately owned and venture capital backed companies to major listed companies, including Smiths Group, Autoliv and Honeywell. David's key focus is early stage businesses with innovative technologies, and he has experience in raising funding, organic business growth, acquisitions and has achieved successful trade sale exists for investors

Dr Marilyn Orcharton
Non-Executive Director

A serial entrepreneur, Marilyn is a qualified dentist with a medal of Honour from the British Dental Association, and her first business was a dental practice. She co-founded Denplan Limited in 1986, which is still the UK's market leader in dental insurance, with a multi-million pound annual turnover. Marilyn sold her stake in Denplan in 1992 and founded Kite Consultants Ltd, which has researched and developed ISOPLAN, a unique business management software package for professional outlets: dentists, doctors, nursing homes and lawyers. She is a founder member of the Entrepreneurial Exchange and has been an honouree of the Leading Women Entrepreneurs. Marilyn was also a visiting surgeon at the University of Glasgow and the first woman to be a dental advisor to the Medical Defence Union and president of the Glasgow Chamber of Commerce. She also has a diploma in marketing and is a member of the Chartered Institute of Marketing.


Alan Greenberg
VP WideAcademy and Group Non-Executive Director

Alan has a wealth of experience in nurturing start-up companies in Education Technologies, and Healthcare sectors, globally. He was previously Head of Higher Education at Apple EMEA, then Apple Education Director, China. His team were responsible for building the technologies behind Podcasting and iTunes U. Alan's appointment is to create the thought leadership and advocacy strategies for WideAcademy.


Key Shareholders as at 30 January 2017 which hold more than 3% in the Company

Shareholder Number of Ordinary Shares Share Capital (%)
João Andrade 8,020,000 14.8%
Lopes Gil 8,020,000 14.8%
Miton Group 4,545,455 8.4%
Dominus Investments 4,311,386 8.0%
Joseph Ferreira 3,836,292 7.1%
Luis Gil 3,776,000 7.0%
Graham Hine 3,198,698 5.9%
Shareholders with >5% 35,707,831 66.1%
David Bridgland 252,552 0.5%
Marilyn Orcharton 135,952 0.3%
Shares not in Public Hands 36,096,335 66.8%
Shares in Public Hands 18,061,726 33.2%
Total Shares IPO 54,058,061 100.0%


Company Secretary

David Vernon Bridgland

Registered Office

Core Technology Facility
46 Grafton Street
M13 9NT


Smaller Company Capital Limited
3rd Floor
15 Eldon Street

Shard Capital Partners LLP
23rd Floor
20 Fenchurch Street

Solicitors to the Company

Fladgate LLP
16 Great Queen Street

Auditors and Reporting Accountants

3 Hardman Street
M3 3AT

Public Relations

St Brides Partners Limited
3 St Michael’s Alley


Share Registrars Limited
Suite E, First Floor
9 Lion and Lamb Yard

WideCells Group Timeline

View All

Columns Including WDC


Market Reports Including WDC


Executive video interviews


© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.